Medacta Delivers 18.5% Constant-Currency Revenue Growth in 2025 on Broad-Based Demand

Medacta Group SA ( (CH:MOVE) ) just unveiled an announcement.

Medacta Group SA reported another year of robust, above-market expansion in 2025, with preliminary unaudited revenue rising 18.5% in constant currency (15.8% in euro) to €683.8 million, driven by double-digit growth in all major regions and product lines. Asia-Pacific and North America led geographic performance with growth of 23.0% and 19.0% respectively, while Latin America surged 42.2%, and the acquisition and integration of Parcus Medical contributed roughly 1.5% to group sales; across business lines, knee and extremities posted particularly strong increases, supported by Medacta’s AMIS hip platform, Kinematic Alignment and GMK SpheriKA knee technologies, and NextAR augmented reality systems in shoulder and spine, underscoring the company’s innovation-led growth strategy, ongoing supply-chain optimization through a new automated warehouse in Italy, and continued investment in its global workforce with the creation of 258 new jobs.

The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF183.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.

More about Medacta Group SA

Medacta Group SA is a Swiss-based global medical technology company specializing in the design, production and distribution of innovative, personalized and sustainable solutions for joint replacement, sports medicine and spine surgery. Founded in 1999, it focuses on minimally invasive techniques and patient-specific technologies, supported by a strong surgeon education platform through its M.O.R.E. Institute, and operates in more than 70 countries worldwide.

Average Trading Volume: 13,147

Technical Sentiment Signal: Buy

Current Market Cap: CHF3.3B

For an in-depth examination of MOVE stock, go to TipRanks’ Overview page.